Skip to main content
Journal cover image

Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant.

Publication ,  Journal Article
Naguib, H; Katz-Greenberg, G; Harris, M; Gommer, J; Yang, LZ; Erkanli, A; Byrns, J
Published in: J Pharm Pract
December 2024

Objectives: Tacrolimus remains the mainstay of immunosuppression in kidney transplantation. Understanding the relationship between therapeutic tacrolimus levels and outcomes of acute rejection, patient/graft survival, and tolerability are important. The relationship between time to therapeutic tacrolimus levels and outcomes has not been well established, specifically with the use of extended release tacrolimus formulation (LCP-Tac). This study investigated time to therapeutic tacrolimus levels of 2 tacrolimus formulations, LCP-Tac and immediate release tacrolimus (IR-Tac), as a predictor of clinical outcomes. Methods: This was a single-center, retrospective, cohort study of kidney transplant recipients at Duke Hospital between 2013-2021. The primary objective evaluated the difference in time to therapeutic tacrolimus levels with LCP-Tac vs IR-Tac regimens. Secondary endpoints included time within therapeutic range during the first 3 months post-transplant, incidence of biopsy-proven rejection, development of de novo donor specific antibodies, and patient and allograft survival at 12 months post-transplant. Results: 128 patients were included (63 in LCP-Tac group and 65 in IR-Tac group). The time to therapeutic tacrolimus level was similar between formulations (7.2 days with LCP-Tac compared to 6.7 days with IR-Tac, P = .63). The time within therapeutic range during the first 3 months post-transplant, via modified Rosendaal, was similar with LCP-Tac and IR-Tac (56.1% vs 64.8%, respectively). Rates of biopsy-proven acute rejection at 12 months were similar (7/63 (11.1%) compared to 4/65 (6.2%)). There was no difference in patient/graft survival between groups. Conclusions: The time to therapeutic tacrolimus levels did not differ based on tacrolimus formulation and was not correlated with clinical outcomes.

Duke Scholars

Published In

J Pharm Pract

DOI

EISSN

1531-1937

Publication Date

December 2024

Volume

37

Issue

6

Start / End Page

1283 / 1290

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tacrolimus
  • Retrospective Studies
  • Pharmacology & Pharmacy
  • Middle Aged
  • Male
  • Kidney Transplantation
  • Immunosuppressive Agents
  • Humans
  • Graft Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Naguib, H., Katz-Greenberg, G., Harris, M., Gommer, J., Yang, L. Z., Erkanli, A., & Byrns, J. (2024). Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant. J Pharm Pract, 37(6), 1283–1290. https://doi.org/10.1177/08971900241248862
Naguib, Hannah, Goni Katz-Greenberg, Matt Harris, Jennifer Gommer, Lexie Z. Yang, Alaattin Erkanli, and Jennifer Byrns. “Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant.J Pharm Pract 37, no. 6 (December 2024): 1283–90. https://doi.org/10.1177/08971900241248862.
Naguib H, Katz-Greenberg G, Harris M, Gommer J, Yang LZ, Erkanli A, et al. Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant. J Pharm Pract. 2024 Dec;37(6):1283–90.
Naguib, Hannah, et al. “Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant.J Pharm Pract, vol. 37, no. 6, Dec. 2024, pp. 1283–90. Pubmed, doi:10.1177/08971900241248862.
Naguib H, Katz-Greenberg G, Harris M, Gommer J, Yang LZ, Erkanli A, Byrns J. Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant. J Pharm Pract. 2024 Dec;37(6):1283–1290.
Journal cover image

Published In

J Pharm Pract

DOI

EISSN

1531-1937

Publication Date

December 2024

Volume

37

Issue

6

Start / End Page

1283 / 1290

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tacrolimus
  • Retrospective Studies
  • Pharmacology & Pharmacy
  • Middle Aged
  • Male
  • Kidney Transplantation
  • Immunosuppressive Agents
  • Humans
  • Graft Survival